User profiles for "author:Antonio Agostini"

Antonio Agostini

Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS
Verified email at unicatt.it
Cited by 390

[HTML][HTML] Immunogenic cell death: an emerging target in gastrointestinal cancers

M Chiaravalli, A Spring, A Agostini, G Piro, C Carbone… - Cells, 2022 - mdpi.com
Immunogenic cell death (ICD) is a regulated form of cell death that induces the activation of
both innate and adaptive immune responses through the release of damage-associated …

[HTML][HTML] KRAS-dependency in pancreatic ductal adenocarcinoma: mechanisms of escaping in resistance to KRAS inhibitors and perspectives of therapy

E Gurreri, G Genovese, L Perelli, A Agostini… - International journal of …, 2023 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is still one of the deadliest cancers in oncology
because of its increasing incidence and poor survival rate. More than 90% of PDAC patients …

CircRNAs and fusion-circRNAs in cancer: new players in an old game

G Visci, D Tolomeo, A Agostini, D Traversa, G Macchia… - Cellular …, 2020 - Elsevier
Circular RNAs (circRNAs) are generated from'back-splicing'events. Their circular structure
makes them stable in cells and body fluids. These entities are involved in several human …

[HTML][HTML] Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination …

C Carbone, G Piro, A Agostini, P Delfino… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Background Complex tumor and immune microenvironment render pancreatic ductal
adenocarcinoma (PDAC) resistant to immune checkpoint inhibitors (ICIs). Therefore, a …

Cytogenetic and molecular profile of endometrial stromal sarcoma

F Micci, L Gorunova, A Agostini… - Genes …, 2016 - Wiley Online Library
Recent cytogenetic and molecular investigations have improved our understanding of
endometrial stromal tumors, including sarcomas (ESS), and helped redefine their …

CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer

G Piro, C Carbone, A Agostini, A Esposito… - British Journal of …, 2023 - nature.com
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with
few therapeutic options available. Despite immunotherapy has revolutionised cancer …

[HTML][HTML] Understanding tricky cellular and molecular interactions in pancreatic tumor microenvironment: New food for thought

A Agostini, A Orlacchio, C Carbone… - Frontiers in …, 2022 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) represents 90% of all pancreatic cancer cases
and shows a high mortality rate among all solid tumors. PDAC is often associated with poor …

PVT1: a long non-coding RNA recurrently involved in neoplasia-associated fusion transcripts

D Tolomeo, A Agostini, G Visci, D Traversa… - Gene, 2021 - Elsevier
NGS technologies and bioinformatics tools allow the rapid identification of chimeric
transcripts in cancer. More than 40,000 fusions are so far reported in the literature; however …

[HTML][HTML] The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)—What Future Prospects Are There for Its Use in Clinical Practice?

M Panebianco, C Ciccarese, A Strusi, V Beccia… - Cancers, 2024 - mdpi.com
Simple Summary In recent years the first-line treatment of advanced renal cancer cell was
implemented by new combination strategy. However, despite numerous research efforts, the …

Recycling the insoluble residue from titania slag dissolution (tionite) in clay bricks

M Dondi, G Guarini, M Raimondo, C Zanelli… - Ceramics …, 2010 - Elsevier
Tionite is the insoluble residue from the titania slag dissolution process for TiO2
manufacturing. It is a fine-grained sludge consisting of rutile, anatase, amorphous phase …